Richard Langley

Professor

Dalhousie University

Canada

Research Interests

Explore related searches

Professors in Canada Professors in Immunology Immunology professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Richard Langley is a Professor at Dalhousie University, Canada. His research primarily focuses on the safety and efficacy of biologic treatments for moderate to severe psoriasis and atopic dermatitis. Recent articles highlight his work on key therapies such as bimekizumab, guselkumab, secukinumab, and tralokinumab, including long-term safety analyses and treatment outcomes.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (5)

Richard B Warren

Manchester University NHS Foundation Trust

UNITED KINGDOM

View details

Diamant Thaçi

University of Lübeck

GERMANY

View details

C. Paul

FRANCE

View details

Morten Otto Alexander Sommer

Technical University of Denmark

DENMARK

View details

Bruce Strober

Clinical Professor

Yale University School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Richard Langley

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial

Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials

Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure

Bimekizumab safety in patients with moderate to severe plaque psoriasis: Pooled data from up to three years of treatment in randomized phase 3 trials.

Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, phase 2b trial (IASOS).

Secukinumab versus guselkumab in the complete resolution of ustekinumab-resistant psoriatic plaques: The ARROW study.

Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.

Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab.

Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3.

Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance.

Collaborators (5)

Richard B Warren

Diamant Thaçi

C. Paul

Morten Otto Alexander Sommer

Bruce Strober

Make your next move.